Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Depreciation & Amortization (CF) (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $22817.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 5.42% year-over-year to $22817.0; the TTM value through Sep 2025 reached $87112.0, up 0.88%, while the annual FY2024 figure was $84071.0, 0.59% up from the prior year.
  • Depreciation & Amortization (CF) reached $22817.0 in Q3 2025 per GANX's latest filing, up from $22328.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $23589.0 in Q4 2023 and bottomed at $2158.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $16479.3, with a median of $20239.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 827.76% in 2022, then decreased 9.67% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $5788.0 in 2021, then skyrocketed by 212.89% to $18110.0 in 2022, then soared by 30.25% to $23589.0 in 2023, then decreased by 9.67% to $21307.0 in 2024, then increased by 7.09% to $22817.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $22817.0 in Q3 2025, $22328.0 in Q2 2025, and $20660.0 in Q1 2025.